Use of extracellular matrix (ECM) as a submucosal fluid cushion in the esophagus
The ECM hydrogel addresses the challenge of separating mucosa and submucosa from the muscularis propria in the esophagus by forming a cushion for endoscopic resection, improving lesion removal efficacy and reducing inflammation.
Patent Information
- Application Number
- KR1020217002119
- Authority / Receiving Office
- KR · KR
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2018-06-21
- Filing Date
- 2019-06-20
- Publication Date
- 2026-11-06
- Estimated Expiration
- 2039-06-20
AI Technical Summary
Current endoscopic procedures for separating the mucosa and submucosa from the muscularis propria in the esophagus are limited by the lack of effective materials that can form a submucosal cushion to facilitate minimally invasive resection of pathological lesions while minimizing inflammation and tissue damage.
The use of an extracellular matrix (ECM) hydrogel, derived from tissues other than the bladder, is injected submucosally to create a cushion between the submucosa and the muscularis propria, providing a suitable gelation time, viscosity, and stiffness for endoscopic resection, and inhibiting inflammation.
The ECM hydrogel effectively separates the mucosa and submucosa from the muscularis propria, facilitating endoscopic resection by forming a cushion that reduces inflammation and supports lesion removal, enhancing the efficacy of procedures like EMR and ESD.
Smart Images

Figure 112021008238424-PCT00003_ABST
Abstract
Description
Technology Field
[0001] Cross-reference of related applications
[0002] This application claims the benefit of U.S. provisional application No. 62 / 688,195 filed on June 21, 2018, the entirety of which is incorporated by reference herein.
[0003] field
[0004] This relates to the use of an extracellular matrix (ECM) hydrogel as a submucosal cushion for endoscopic resection, particularly for separating the mucosa and submucosa from the muscularis propria of the esophagus, wherein the ECM hydrogel is not a urinary bladder ECM hydrogel. Background Technology
[0005] Endoscopy is a procedure that allows the examination of hollow organs or body cavities using a tool called an endoscope without the use of invasive surgery. Endoscopy can be used for surgical procedures such as the cauterization of bleeding vessels, the removal of polyps, adenomas, and small tumors, performing biopsies, or removing foreign bodies. Endoscopy can be performed through small incisions in the gastrointestinal tract, respiratory tract, ear, urinary tract, and female reproductive system, as well as in normally closed body cavities such as the abdominal cavity or pelvic cavity (laparoscopy), the interior of a joint (arthroscopy), and organs of the chest (thoracoscopy and mediastinoscopy). An endoscope is an illuminated, flexible or rigid tubular instrument, typically made of optical fiber, for visualizing the interior of a hollow organ or part (e.g., the esophagus) for diagnostic or therapeutic purposes, having one or more working channels that allow the passage of instruments (e.g., forceps, electrosurgical knives, endoscopic needles, or scissors) or facilitate the removal of biological specimens. It contains an appropriate lamp and imaging device in the distal portion and can be inserted through natural openings of the body, such as the mouth, anus, ears, or nose, or through a small surgical incision.
[0006] Endoscopy is widely applied to the gastrointestinal tract. For example, endoscopy can be used to examine the mucosa covering the gastrointestinal cavity and to detect large and small pathological lesions such as inflammatory tissue, polyps, pseudopolyps, serrated lesions, adenomas, ulcers, dysplasia, pre-neoplastics, and tumor formations. Endoscopy can be used for biopsy and removal of pathological lesions (polyps, adenomas, dysplasia, Barrett's dysplasia, pre-neoplastics, and tumor formations). Surgical interventions include two types of endoscopic resections commonly used in gastrointestinal endoscopy to remove pathological lesions: endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD). These two techniques allow for the minimally invasive treatment of gastric polyps, adenomas, dysplasia, Barrett's dysplasia, and early-stage cancers while minimizing the risk of lymph node metastasis. The need for materials used in endoscopy in the esophagus remains. Prior art literature
[65535] US 6,893,666 B2 (2005.05.17.)US 8,361,503 B2 (2013.01.29.) Wolf et al. A hydrogel derived from decellularized dermal extracellular matrix. Biomaterials 33: 7028-7038, 2012. Badylak et al. Resorbable bioscaffold for esophageal repair in a dog model. J Pediatr Surg. 35(7):1097-103, 2000. Badylak et al. Esophageal reconstruction with ECM and muscle tissue in a dog model. J. Surg. Res. September 2005; 128(1):87-97, 2005. Keane et al., Tissue Eng. Part A, 21(17-18): 2293-2300, 2015.
[0007] A method for separating the mucosa and submucosa from the inferior muscle in the esophageal region of a subject is disclosed in this application. These methods include: a pharmaceutical composition comprising an extracellular matrix (ECM) hydrogel being injected submucosally into the esophageal region of a subject to form a cushion between the submucosa and the inferior muscle in the esophagus, wherein the ECM hydrogel has the following characteristics: a) a 50% gelation time of less than 30 minutes at a temperature of about 37 °C; b) a flow viscosity suitable for injection into the esophagus; and c) a stiffness of about 10 to about 400 Pascals (Pa). By doing so, the mucosa and submucosa are incised from the inferior muscle in the esophageal region. In some embodiments, the method also suppresses inflammation of the esophagus in the subject. The ECM hydrogel is not a bladder ECM hydrogel.
[0008] In other embodiments, these methods also include: a pharmaceutical composition comprising an extracellular matrix (ECM) hydrogel is injected submucosally into a subject's esophageal region to form a cushion between the submucosal region and the inferior proprioceptive muscle in the esophagus, thereby separating the mucosa and the submucosal region from the inferior proprioceptive muscle in the esophageal region. In some embodiments, the method also inhibits inflammation of the esophagus in the subject. The ECM hydrogel is not a bladder ECM hydrogel.
[0009] In some embodiments, the separation method includes endoscopic mucosal resection or endoscopic mucosal dissection.
[0010] The foregoing features, other features, and advantages of the present invention will become more apparent from the following detailed description with reference to the accompanying drawings. Brief explanation of the drawing
[0011] FIG. 1A-1E. Viscoelastic properties. The viscosity profiles of ELEVIEW™ and esophageal ECM (eECM) 12 mg / mL were tested at 10 °C while increasing the shear rate (0.1 - 1000 1 / s). A To induce gelation and measure the maximum storage (G') and loss (G'') factors, the temperature was rapidly raised to 37 ℃ ( B ). The representative graph of a time sweep is ELEVIEW™ ( C eECM hydrogel at ) and 12 mg / mL ( D It is indicated as ). The time to 50% gelation at eECM 12 mg / mL was measured, but ELEVIEW TM Because it was not gelled, ELEVIEW TM Could not be measured (G'' > G' during time sweep test) E ). FIG. 2A-2B. Mucoadhesive strength.The mucosal adhesion strength of ELEVIEW™ and eECM 12 mg / mL was porcine esophageal muscle ( A ) or esophageal mucosa ( B It was applied to ). Fig. 3 . Macrophage activation Macrophage expression of anti-inflammatory and pro-inflammatory markers after exposure to eECM and ELEVIEW™. Figs. 4A-4C. Submucosal fluid cushion - esophagus. Measurement of submucosal fluid cushion height over time after ECM (eECM) injection compared with ELEVIEW™ in the esophageal submucosal area ( A ). Appearance of tissue 75 minutes after injection of 2 mL of test agent ( B Isolation and exposure of the test substance after 75 minutes ( C ). Specific details for implementing the invention
[0012] The present application discloses the use of an extracellular matrix (ECM) hydrogel as a submucosal cushion to separate the mucosa and submucosa from the proper muscle of the esophagus in any endoscopic resection, such as EMR and ESD, which are commonly used to remove pathological lesions in esophageal endoscopy. The ECM hydrogel is not a bladder ECM hydrogel.
[0013] Terms
[0014] Unless otherwise specified, technical terms are used according to common usage. Definitions of common terms in molecular biology can be found in Benjamin Lewin, Genes V, published by Oxford University Press, 1994 (ISBN 0-19-854287-9); Kendrew et al. (eds.), The Encyclopedia of Molecular Biology, published by Blackwell Science Ltd., 1994 (ISBN 0-632-02182-9); and Robert A. Meyers (ed.), Molecular Biology and Biotechnology: a Comprehensive Desk Reference, published by VCH Publishers, Inc., 1995 (ISBN 1-56081-569-8).
[0016] To facilitate the examination of various embodiments of the present disclosure, the following description of specific terms is provided:
[0017] Acid Protease : As an enzyme that cleaves peptide bonds, the activity of this enzyme in cleaving peptide bonds increases at acidic pH. For example, acidic proteases include, but are not limited to, pepsin and trypsin.
[0018] Barrett's Esophagus: Generally, an abnormal change (metaplasia or dysplasia) in the esophageal cells of the lower (distal) portion of the esophagus. Barrett's esophagus is diagnosed when the normal stratified squamous epithelial lining of the esophagus is replaced by simple columnar epithelium containing goblet cells. Barrett's esophagus is found in 5 to 15% of patients being treated for gastroesophageal reflux disease (GERD), but a large subgroup of patients with Barrett's esophagus are asymptomatic. Barrett's esophagus is closely associated with esophageal adenocarcinoma and is considered a precancerous condition. The primary cause of Barrett's esophagus is considered to be adaptation to chronic exposure to acid due to reflux esophagitis. After a biopsy, cells of Barrett's esophagus are classified into four general categories: non-dysplastic, low-grade dysplasia, high-grade dysplasia, and frank carcinoma.
[0019] Base: A compound or a solution of a compound having a pH greater than 7. For example, the base includes, but is not limited to, an alkali hydroxide or an aqueous solution of an alkali hydroxide. In certain embodiments, the base is NaOH or NaOH in PBS.
[0020] Comminute (comminution and comminuting):A process of reducing large particles into small particles, including but not limited to grinding, blending, shredding, slicing, milling, cutting, and shredding. The extracellular matrix (ECM) may be ground while in any form, including but not limited to hydrate form, frozen, air-dried, lyophilized, powdered, and sheet form.
[0021] diagnosis ( Diagnosis : The process of identifying a disease based on signs, symptoms, and various test results. The conclusion reached through this process is also called a "diagnosis." Types of tests commonly performed include blood tests, medical imaging, and biopsies.
[0022] Dissection: For example, the process of separating or cutting tissue during surgery.
[0023] Endoscopic injection needles or endoscopic injection needle catheters or endoscopic injection needle catheters A device comprising a long catheter with an internal injection tube having a distal injection needle that is generally long (e.g., up to approximately 230 cm) and slidably positioned. Typically, a proximal operating handle is coupled to the catheter and injection tube to move one relative to the other. The needle can be retracted. Access to fluid in the injection tube is typically provided through a Luer connector on the handle.
[0024] The endoscopic injection needle is typically delivered to the injection site through the catheter of the endoscope. To protect the lumen from damage, the handle of the injection needle device is operated to withdraw the distal injection needle into the lumen of the catheter before inserting the device into the endoscope. When the distal end of the endoscopic injection needle device is positioned at the injection site, the handle is operated to move the injection needle from the lumen of the catheter to the distal end. In some embodiments, when advanced to the most distal position, the exposed portion of the injection needle may be about 4-6 mm in length.
[0025] Endoscopic Mucosal Resection (EMR): This is an endoscopic technique developed to remove adhesive or flat neoplasms confined to the surface layers (mucosa and submucosa) of the gastrointestinal (GI) tract. The mucosa and submucosa are resected from the inferior propria. Endoscopic submucosal dissection (ESD) EMR refers to an endoscopic technique specifically developed to remove larger lesions, such as those in the gastrointestinal tract, where the mucosa and submucosa are separated from other layers of the tract. EMR and ESD generally involve injecting material beneath the target lesion—between the submucosa and the inferior propria—to act as a cushion and elevate the submucosa and superior mucosa. With EMR, the elevated lesion is removed using a snare and moved into a small cup via suction. With ESD, the submucosa beneath the lesion is separated from the superior mucosa by separating it with a specialized knife. ESD can remove lesions that are larger and potentially deeper than those achievable with therapeutic EMR. Both EMR and ESD are facilitated by injecting material into the submucosa of the organ, which effectively separates the superior mucosa from the inferior propria while simultaneously elevating the mucosa above the adjacent esophageal mucosa. This separation of layers and the elevation of the affected tissue aid the surgeon in isolating, grasping, and removing the tissue of interest.
[0026] Extracellular Matrix (ECM):Non-cellular components of tissues and organs. Natural ECM (found in multicellular organisms such as mammals and humans) is a mixture of structural and non-structural biomolecules, including but not limited to collagens, elastins, laminins, glycosaminoglycans, proteoglycans, antimicrobials, chemoattractants, cytokines, and growth factors, and generally differs in specific composition between different tissues and organs. In mammals, ECM often contains various forms of collagen, accounting for about 90% by dry weight. A biologic scaffold composed of ECM can be created by removing cells from a given tissue or organ left behind. The composition and structure of ECM vary depending on the tissue source. For example, the small intestine submucosa (SIS), urinary bladder matrix (UBM), esophagus (E), and liver stroma ECM differ in their overall structure and composition due to the unique cellular niches required by each tissue. The "extracellular matrix" and "intact ECM" bioscaffolds are composed of undissolved extracellular matrix, maintain a three-dimensional microstructure, and retain the activity of structural and non-structural biomolecules, including collagen, elastin, laminin, glycosaminoglycans, proteoglycans, antimicrobial agents, chemotaxis, cytokines, and growth factors, but not limited to the comminuted ECM as described herein.
[0027] The activity of biomolecules within the ECM can be altered chemically or mechanically, for example, by chemical or enzymatic cross-linking and / or ECM dialyzing. Intact ECM is not inherently enzymatically digested, cross-linked, and / or dialyzed, which means that the ECM has not undergone the processes of digestion, dialyzing, and / or cross-linking, or that these are not conditions that occur naturally during the storage and handling of the ECM prior to dissolution. Therefore, dialyzed ECM (except for minor methods that do not substantially affect the gelation and functional properties of the ECM in the use described in this application) is not considered "intact."
[0028] Esophagogastroduodenoscopy (EGD) or Upper Gastrointestinal Endoscopy: It is a diagnostic endoscopy that visualizes the upper gastrointestinal tract up to the duodenum. "Esophageal endoscopy" is any endoscopy that visualizes the esophagus. Endoscopy may sometimes be performed as part of an EGD or upper gastrointestinal endoscopy. Unless explicitly stated otherwise, these terms are not mutually exclusive.
[0029] Gelation The formation of a gel in a sol.
[0030] Gastroesophageal Reflux Disease (GERD): Chronic symptoms of mucosal damage caused by the reflux of stomach acid from the stomach into the esophagus. GERD is usually caused by changes in the barrier between the stomach and esophagus, such as abnormal relaxation of the lower esophageal sphincter, which keeps the upper (proximal) part of the stomach closed, impaired expulsion of the stomach from the esophagus, or a hiatal hernia. These changes can be permanent or temporary.
[0031] Flow Viscosity:Measurement of a fluid's resistance to gradual deformation caused by shear or tensile stress. Viscosity is a property of a fluid that opposes the relative motion between two surfaces of the fluid when the fluid moves at different speeds. When a fluid passes through a tube, the particles composing the fluid generally move faster near the tube axis and slower near the walls. Stress (such as the pressure difference between the two ends of the tube) is required to overcome friction between layers of particles to keep the fluid moving. The stress required for a given velocity pattern is proportional to the viscosity of the fluid. Viscosity is measured using viscometers and rheometers. Viscosity can be measured in Pascal-seconds (Pa*s). The viscosity of water at 20 °C is 1.002 mPa*s.
[0032] Hydrogel: It is a network of hydrophilic polymer chains, sometimes found as a colloidal gel where water is the dispersion medium. Hydrogels are networks of highly absorbent natural or synthetic polymers. Hydrogels also possess flexibility similar to natural tissues. The term "urinary bladder ECM hydrogel" includes urinary bladder matrix (UBM) and urinary bladder submucosa (UBS) hydrogels.
[0033] Inflammation A localized reaction triggered by tissue damage. Inflammation is characterized by the appearance or migration of all types of leukocytes into tissue spaces, units, or sites in numbers exceeding those cells found within such tissue sites under normal (healthy) conditions. Inflammation is mediated by the complex biological response of vascular tissue to harmful stimuli, such as pathogens, damaged cells, or irritants.
[0034] Isotonic Buffered Solution A solution buffered between pH 7.2 and 7.8 and having a balanced salt concentration to promote an isotonic environment.
[0035] Low Grade Dysplasia and High Grade Dysplasia and Metaplasia: The pathological condition is characterized by abnormal cell morphology, but the cell type can still be recognized as squamous epithelium. Generally, in esophageal dysplasia, apical mucin is absent in the internal lining cells of the esophagus. At low magnification, these areas may appear more hyperchromatic compared to unrelated areas.
[0036] In the case of high-grade dysplasia, changes in cell morphology are more pronounced, but the cells are still technically a type of squamous epithelium.
[0037] When cells transform from squamous epithelial cells into other cell types, such as glandular cells that are typically cuboidal or columnar, the process is called metaplasia. In cases of metaplasia, distortions of the glandular structure of the esophagus are generally present and may be manifested. These consist of branching and lateral budding of crypts, arrangement of villi on the mucosal surface, or intraglandular bridging of the epithelium to form a "back-to-back" cribriform pattern. There is abnormal epithelium on the mucosal surface characterized by a loss of nuclear polarity, marked by the "rounding up" of nuclei, and a lack of consistent nuclear relationships.
[0038] Prevention or treating:Disease inhibition refers to suppressing the partial or complete development of a disease in a person at risk of developing it, such as a disease caused by inflammation. Examples of people at risk of esophageal adenocarcinoma include those with Barrett's esophagus or GERD. Inhibiting the disease process involves preventing the onset of the disease. "Treatment" refers to therapeutic interventions that improve the signs or symptoms of a disease or pathological condition after the disease has developed.
[0039] Shear Stress: The component of stress coplanar with respect to the material cross-section. Shear stress occurs in the force vector component parallel to the cross-section. The formula for calculating average shear stress is force per unit area.
[0040]
[0041] Here, T = shear stress, F = applied force, A = cross-sectional area of the material parallel to the applied force vector.
[0042] Stricture:A narrowing or constriction of the esophagus that causes difficulty swallowing. Symptoms of esophageal stricture include heartburn, a bitter or acidic taste in the mouth, choking, coughing, shortness of breath, burping or hiccups, pain or trouble swallowing, vomiting blood, and / or weight loss. Esophageal stricture can be caused by gastroesophageal reflux disease, esophagitis, a dysfunctional lower esophageal sphincter, disordered motility, lye ingestion, or a hiatal hernia. Strictures can form after esophageal surgery and other treatments such as laser therapy or photodynamic therapy. As the site heals, scarring forms, causing the tissue to be pulled and constricted, making swallowing difficult. Strictures can be the result of inflammation. Esophageal strictures can be diagnosed using a barium swallow test or upper gastrointestinal endoscopy.
[0043] stiffness ): The hardness of an object or fluid. The hardness of the ECM is important for guiding cell movement along a durotaxis. Hardness can be measured in Pascals (Pa), which is 1 Newton per square meter.
[0044] therapeutic agent:It is used in a general sense and includes treating agents, prophylactic agents, and replacement agents. "Treatment" or "treating" means providing a patient with a substance, such as an ECM hydrogel, in an amount sufficient to reduce, suppress, or alleviate any disease symptoms to some extent, slow disease progression, or induce disease regression. In certain embodiments, treatment of the disease may begin before the patient exhibits symptoms of the disease. The disclosed method suppresses esophageal inflammation and / or alleviates the effects of esophageal inflammation.
[0045] Therapeutically effective amount: The "therapeutically effective amount" of a composition such as an ECM hydrogel refers to an amount effective in providing the therapeutic benefit of symptom improvement when administered to a patient. An amount of ECM hydrogel is therapeutically effective if it is sufficient to achieve the desired effect in the subject being treated, such as forming a gel and separating the upper mucosa from the lower proprioceptive muscle when injected into the submucosal tissue of the esophagus. The effective amount for forming a submucosal cushion depends on the agent applied, the subject being treated, the severity and type of pain, and the method of administration.
[0046] The ECM hydrogel used in the method disclosed in this application is applied in both medical and veterinary settings. Accordingly, the general terms “subject” or “patient” are understood to include all animals, including but not limited to humans or other primates, and veterinary subjects such as dogs, cats, horses, and cattle.
[0047] Urinary Bladder ECM:Extracellular matrix extracted from the bladder of all mammals. The term includes urinary bladder matrix (UBM) ECM and urinary bladder submucosa (UBS) ECM. The wall of the bladder consists of the following layers: tunica mucosa (including the transitional epithelium layer and tunica propria) listed in a thickness section from the luminal to the abluminal lateral side, a submucosal layer, up to three muscle layers, and adventitia (a loose connective tissue layer). UBS is prepared from a tissue composition comprising bladder submucosal tissue exfoliated from the abluminal muscle layer and at least the luminal portion of the mucosa of a segment of a vertebrate bladder (see U.S. Patent No. 5,554,389 incorporated herein by reference). UBM ECM is prepared from the urinary bladder epithelial basement and the lamina propria located immediately beneath the basement membrane (see U.S. Patent No. 6,576,265 incorporated by reference in this application). The disclosed method does not use a hydrogel produced from bladder ECM.
[0048] Unless otherwise stated, all technical and scientific terms used in this application have the same meaning as generally understood by those skilled in the art to which this disclosure pertains. The singular terms “a,” “an,” and “the” include plural objects unless the context otherwise indicates. Similarly, the word “or” is intended to include “and” unless the context otherwise indicates. It should be further understood that all base sizes or amino acid sizes and all molecular weights or molecular mass values provided for nucleic acids or polypeptides are approximations and are provided for illustrative purposes. Methods and materials similar or equivalent to those described in this application may be used to practice or test the contents of this disclosure, but suitable methods and materials are described below. The term “comprises” means “includes.” The term “about” indicates within 5%. All publications, patent applications, patents, and other references mentioned in this application are incorporated by reference in their entirety. In the event of a conflict, this description, including the definition of terms, shall prevail. Additionally, materials, methods, and examples are for illustrative purposes only and are not intended to be restrictive.
[0049] Extracellular matrix (ECM) hydrogel
[0050] A method for manufacturing an ECM hydrogel is disclosed, for example, in U.S. Patent No. 8,361,503. Any type of extracellular matrix tissue may be used to produce a hydrogel that can be used in a method as disclosed herein (U.S. Patent Nos. 4,902,508; 4,956,178; 5,281,422; 5,352,463; 5,372,821; 5,554,389; 5,573,784; 5,645,860; 5,771,969; 5,753,267; 5,762,966; 5,866,414; 6,099,567; 6,485,723; 6,576,265; 6,579,538; 6,696,270; 6,783,776; 6,793,939; 6,849,273; 6,852,339; 6,861,074; 6,887,495; 6,890,562; 6,890,563; 6,890,564; and 6,893,666 are associated with ECM). In certain embodiments, ECM is isolated from warm-blooded mammalian vertebrates, including but not limited to, humans, monkeys, horses, pigs, cattle, and sheep. In certain non-limiting examples, ECM is a pig or a human.
[0051] The ECM may be derived from any organ or tissue other than the bladder, including but not limited to the intestine, liver, esophagus, and dermis. The ECM may be derived from the kidney, heart, uterus, brain, blood vessels, lungs, bone, muscle, pancreas, stomach, spleen, or colon. In one embodiment, the ECM is derived from the esophagus. In another embodiment, the ECM is derived from the small intestine or dermis. The ECM may or may not include a portion of the basement membrane of the ECM. In certain embodiments, the ECM includes at least a portion of the basement membrane. In other embodiments, the ECM is obtained from cell culture. The ECM hydrogel may be produced by combining two or more tissue sources.
[0052] U.S. Patent No. 6,893,666, incorporated by reference to this application, also discloses the production of ECM from skin, esophagus, and small intestine. The production of hydrogels from decellularized dermal ECM is disclosed in Wolf et al., Biomaterials 33: 7028-7038, 2012 (incorporated by reference to this application). The production of ECM from esophageal tissue is disclosed, for example, in Badylak et al., J Pediatr Surg. 35 (7): 1097-103, 2000 and Badylak et al., J. Surg. Res. 2005 September; 128 (1): 87-97, 2005 (both incorporated by reference to this application). One of these methods may be used when ECM is not produced in the bladder.
[0053] Commercially available ECM formulations may also be used in the methods, apparatus, and compositions described in this application. In one embodiment, the ECM is derived from the submucosal portion of the small intestine or the SIS. Commercially available formulations are SURGISIS TM , SURGISIS-ES TM , STRATASIS TM and STRATASIS-ES TM (Cook Urological Inc.; Indianapolis, Ind.) and GRAFTPATCH TM Includes, but is not limited to, Organogenesis Inc.; Canton Mass. In other embodiments, the ECM is derived from the dermis. Commercially available formulations contain PELVICOL TM (PERMACOL in Europe) TM Sold as; Bard, Covington, GA), REPLIFORM TM (Microvasive; Boston, Mass.) and ALLODERM. TM (LifeCell; Branchburg, NJ) is included.
[0054] The source tissue used for the preparation of the ECM can be harvested in a wide variety of ways, and once harvested, various parts of the harvested tissue can be used. The ECM was prepared from the esophagus and small intestine, and the hydrogel was prepared from the ECM (e.g., Keane et al., Tissue Eng. Part A, 21 (17-18) : 2293-2300, 2015, incorporated by reference in this application). The esophageal ECM can be prepared by mechanically separating the mucosa and submucosa from the muscularis externa, digesting the mucosal layer in a buffer containing trypsin, and then exposing it to sucrose, TRITON-X100®, deoxycholic acid, peracetic acid, and DNAse. The small intestinal submucosal (SIS) can be prepared by mechanically removing the superficial layers of the mucosa (tunica mucosa), serosa (tunica serosa), and externa (tunica muscularis externa) from an intact small intestine, while leaving the submucosal, muscularis mucosa, and basal stratum compactum intact. The SIS is then treated with peracetic acid. An example protocol is provided in Keane et al.
[0055] In some embodiments, epithelial cells may be exfoliated by first immersing the tissue in a deepithelializing solution containing, but not limited to, 1.0 N hypertonic saline for a period ranging from 10 minutes to 4 hours. Exposure to the hypertonic saline solution can effectively remove epithelial cells from the underlying basement membrane. The tissue remaining after the initial exfoliation procedure includes the epithelial basement membrane and a tissue layer far from the lumen of the epithelial basement membrane. This tissue is then subjected to further treatment to remove most of the tissue far from the lumen, excluding the epithelial basement membrane.
[0056] ECM can be disinfected or sterilized by various standard techniques, including but not limited to peracetic acid exposure, low-dose gamma irradiation, gas plasma sterilization, ethylene oxide treatment, supercritical CO2, or electron beam treatment. More generally, disinfection of ECM is achieved by immersion in 0.1% (v / v) peracetic acid, 4% (v / v) ethanol, and 95.9% (v / v) sterile water for 2 hours. Peracetic acid residue is removed by washing twice with PBS (pH = 7.4) for 15 minutes and twice with sterile water for 15 minutes. ECM material can be sterilized by propylene oxide or ethylene oxide treatment, gamma irradiation (0.05 to 4 mRad), gas plasma sterilization, supercritical CO2, or electron beam treatment. ECM can also be treated with glutaraldehyde to induce cross-linking of the protein material, but this treatment substantially alters the material so that it is slowly reabsorbed or not reabsorbed at all, and induces other forms of host remodeling, such as scar tissue formation or encapsulation, which are more closely similar to structural remodeling. Cross-linking of the protein material can also be induced by carbodiimide, dehydrothermal, or photooxidation methods. As disclosed in U.S. Patent No. 8,361,503, the ECM is disinfected by immersing it in 0.1% (v / v) peracetic acid (a), 4% (v / v) ethanol, and 96% (v / v) sterile water for 2 hours. The ECM material is washed twice with PBS (pH = 7.4) for 15 minutes each time, and twice with deionized water for 15 minutes each time.
[0057] After isolation of the tissue of interest, decellularization is performed by exposure to various methods, including but not limited to hyperosmolar saline, peracetic acid, TRITON-X®, or other detergents. Disinfection and decellularization can be performed simultaneously. For example, but not limited to, disinfection with the peracetic acid described above may also serve to decellularize the ECM. The decellularized ECM can be dried by freeze-drying or air drying. The dried ECM can be ground by methods including, but not limited to, tearing, milling, cutting, grinding, and shearing. The ground ECM can also be further processed into a powder form by methods such as grinding or grinding in a frozen or freeze-dried state, for example, but not limited to.
[0058] To prepare solubilized ECM tissue for use in the manufacture of ECM hydrogels, comminuted ECM is digested with an acidic protease in an acidic solution to form a digest solution. The digest solution of the ECM is generally maintained under constant stirring for a certain period of time at room temperature. The ECM digest can be used immediately, stored at -20 °C, or frozen at -20 °C or -80 °C, for example, but not limited to.
[0059] Once the ECM is dissolved, the pH of the solution rises (generally, substantially, completely) to between 7.2 and 7.8, and according to one embodiment, to pH 7.4. Bases containing hydroxyl ions, such as NaOH, can be used to raise the pH of the solution. Similarly, buffers, such as isotonic buffers including but not limited to phosphate-buffered saline (PBS), can be used to bring the solution to a target pH or to help maintain the pH and ionic strength of the gel at target levels, such as physiological pH and ionic conditions. This forms a "pre-gel" solution. The pre-gel is in liquid form as a viscous solution at room temperature. The neutralized digestion solution (pre-gel) can be gelled at a temperature close to 37 °C, where the temperature is close to physiological temperature. In some embodiments, the method does not include a dialysis step prior to gelation and typically produces a more complete ECM-like substrate that gels at 37 °C at a specific rate (see below).
[0060] Therefore, the ECM can typically originate from the dermis, esophagus, small intestine, kidney, liver, heart, uterus, brain, blood vessels, lungs, bone, muscle, pancreas, stomach, spleen, or colon. Since the ECM is not the bladder, it is not a UBM or UBS.
[0061] ECM hydrogels can be produced from two or more tissue sources, such as two, three, or four tissue sources. In one non-limiting embodiment, the ECM is freeze-dried and ground. The ECM is dissolved in an acidic solution with an acidic protease to produce digested ECM, such as esophageal ECM. The acidic protease may be pepsin or trypsin, or a combination thereof, without limitation. The ECM may be dissolved in an acidic pH suitable or optimal for the protease, for example, greater than about pH 2 or between pH 4, for example, in a 0.01 M HCl solution. The solution is generally dissolved for about 12 to about 48 hours, depending on the tissue type (e.g., see examples below), with mixing (stirring, agitation, admixing, blending, rotating, tilting, etc.). The ECM hydrogel is prepared by (i) pulverizing the extracellular matrix, (ii) digesting it with an acidic protease in an acidic solution to dissolve the intact, non-dialyzed or non-cross-linked extracellular matrix to produce a digested solution, (iii) raising the pH of the digested solution to a pH between 7.2 and 7.8 to produce a neutralized digested solution (pregel solution), and (iv) gelling the solution at a temperature of approximately 37 °C within the organ of interest. When the ECM is digested using an acidic protease, the pregel solution and the resulting hydrogel may contain inactivated proteases.
[0062] ECM hydrogels form a gel when exposed to a temperature of approximately 37°C. ECM hydrogels in the "pre-gel" form can be frozen and stored at -20°C or -80°C, for example, but not limited to. ECM hydrogels in the "pre-gel" form can be stored at room temperature, such as approximately 25°C. Therefore, ECM hydrogels are in the pre-gel form at temperatures below 37°C, for example, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, and 4°C. Since ECM hydrogels can be frozen, they can be stored at 0°C or below. As used in this application, the terms “pregel form” or “pregel” refer to an ECM hydrogel that has an increasing pH but is not gelled. For example, but not limited to, an ECM hydrogel in pregel form has a pH between 7.2 and 7.8. The ECM hydrogel can be delivered to a subject in pregel form using an endoscope.
[0063] ECM hydrogels in the form of a pregel can be introduced into a patient's esophagus. When introduced submucosally into the esophagus at approximately 37°C, the ECM hydrogel gels and creates a cushion of ECM hydrogel between the propria and the submucosal esophagus, thereby lifting the submucosal lesion for surgical resection. Without being bound by theory, ECM hydrogels contain many naturally soluble factors, including but not limited to cytokines. Specific characteristics of non-dialyzed (whole ECM) preparations manufactured from various tissues are disclosed herein.
[0064] In some embodiments, the ECM hydrogel has the following characteristics: a) a time to reach 50% gelation of less than 30 minutes at a temperature of about 37 °C; b) a flow viscosity suitable for injection into the esophagus; and c) a hardness of i) about 10 to about 400 Pascal (Pa), ii) about 10 to about 450 Pa; iii) about 10 to about 600 Pa, iv) about 5 to about 1,000 Pa, v) about 10 to 1,000 Pa, or vi) about 10 to about 70 Pa.
[0065] In an example, the ECM hydrogel has the following characteristics: a) a time to 50% gelation of less than 30 minutes at a temperature of about 37 °C; b) a flow viscosity suitable for esophageal injection; and c) a hardness of about 10 to about 300 Pascals (Pa). In another example, the ECM hydrogel has the following characteristics: a) a time to 50% gelation of less than 30 minutes at a temperature of about 37 °C; b) a flow viscosity suitable for esophageal injection; and c) a hardness of about 10 to about 450 Pascals (Pa). In another example, the ECM hydrogel has the following characteristics: a) a time to 50% gelation of less than 30 minutes at a temperature of about 37 °C; b) a flow viscosity suitable for esophageal injection; and c) a hardness of about 10 to about 600 Pascals (Pa).
[0066] In another embodiment, the ECM hydrogel has the following characteristics: a) a time to 50% gelation of less than 30 minutes at a temperature of about 37 °C; b) a flow viscosity suitable for esophageal injection; and c) a hardness of about 5 to about 1,000 Pascals (Pa). In another embodiment, the ECM hydrogel has the following characteristics: a) a time to 50% gelation of less than 30 minutes at a temperature of about 37 °C; b) a flow viscosity suitable for esophageal injection; and c) a hardness of about 10 to about 1,000 Pascals (Pa). In more embodiments, the ECM hydrogel has the following characteristics: a) a time to 50% gelation of less than 30 minutes at a temperature of about 37 °C; b) a flow viscosity suitable for esophageal injection; and c) a hardness of 10 to 70 Pascals (Pa).
[0067] In some embodiments, the ECM hydrogel has the following characteristics: a) a time to reach 50% gelation of less than 30 minutes at a temperature of about 37 °C; b) a flow viscosity suitable for injection into the esophagus; and c) a hardness of i) about 10 to about 400 Pascal (Pa), ii) about 10 to about 450 Pa; iii) about 10 to about 600 Pa, iv) about 5 to about 1,000 Pa, v) about 10 to 1,000 Pa, or vi) about 10 to about 70 Pa.
[0068] In some embodiments, the ECM hydrogel has the following characteristics: a) a time to reach 50% gelation of less than 20 minutes at a temperature of about 37 °C; b) a flow viscosity suitable for injection into the esophagus; and c) a hardness of i) about 10 to about 400 Pascal (Pa), ii) about 10 to about 450 Pa; iii) about 10 to about 600 Pa, iv) about 5 to about 1,000 Pa, v) about 10 to 1,000 Pa, or vi) about 10 to about 70 Pa.
[0069] In an example, the ECM hydrogel has the following characteristics: a) a time to reach 50% gelation of less than 20 minutes at a temperature of about 37 °C; b) a flow viscosity suitable for infusion into the esophagus; and c) a hardness of about 10 to about 300 Pascals (Pa). In another example, the ECM hydrogel has the following characteristics: a) a time to reach 50% gelation of less than 20 minutes at a temperature of about 37 °C; b) a flow viscosity suitable for infusion into the esophagus; and c) a hardness of about 10 to about 450 Pascals (Pa). In another example, the ECM hydrogel has the following characteristics: a) a time to reach 50% gelation of less than 20 minutes at a temperature of about 37 °C; b) a flow viscosity suitable for infusion into the trachea; and c) a hardness of about 10 to about 600 Pascals (Pa).
[0070] In another embodiment, the ECM hydrogel has the following characteristics: a) a time to 50% gelation of less than 20 minutes at a temperature of about 37 °C; b) a flow viscosity suitable for esophageal injection; and c) a hardness of about 5 to about 1,000 Pascals (Pa). In another embodiment, the ECM hydrogel has the following characteristics: a) a time to 50% gelation of less than 20 minutes at a temperature of about 37 °C; b) a flow viscosity suitable for esophageal injection; and c) a hardness of about 10 to about 1,000 Pascals (Pa). In more embodiments, the ECM hydrogel has the following characteristics: a) a time to 50% gelation of less than 20 minutes at a temperature of about 37 °C; b) a flow viscosity suitable for esophageal injection; and c) a hardness of 10 to 70 Pascals (Pa).
[0071] In another embodiment, the ECM hydrogel has a) a time to 50% gelation of less than 10 minutes at about 37 °C; b) a flow viscosity sufficient for injection into the esophagus; c) a hardness of about 10 to about 300 Pascal (Pa); and d) the hydrogel is an esophageal hydrogel.
[0072] In certain non-limiting examples, the ECM hydrogel is an esophageal hydrogel. In other certain non-limiting examples, the ECM hydrogel may be produced from two or more tissue sources. In additional non-limiting examples, the ECM hydrogel may be produced from the dermis, esophagus, or small intestine. The ECM hydrogel is not a bladder ECM hydrogel.
[0073] In additional specific non-limiting examples, the ECM hydrogel comprises the steps of: (a) digesting tissue with an acidic protease in an acidic solution to dissolve the acellular extracellular matrix (ECM) and produce digested ECM; (b) raising the pH of the digested ECM to a pH between 7.2 and 7.8 to produce a neutralized digested solution; and (c) diluting the digested ECM into an ECM hydrogel at a concentration of about 2 mg / ml to about 16 mg / ml, e.g., about 8 mg / ml to about 12 mg / ml. This hydrogel is introduced into the esophagus of a subject and gelled. In one non-limiting example, the ECM may be an esophageal ECM.
[0074] The ECM hydrogel used in the method disclosed in this application has a 50% gelation time of less than 30 minutes to less than 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, and 3 minutes at a temperature of about 37 °C. In some embodiments, the ECM hydrogel has a time to reach 50% gelation of less than 10 minutes at a temperature of about 37 °C. In some embodiments, the time to reach 50% gelation is about 2 to about 30 minutes at about 37 °C. In additional embodiments, the time to reach 50% gelation is about 2 to about 10 minutes at about 37 °C. In more embodiments, the time to 50% gelation is about 3 to about 10 minutes. In other embodiments, the time to 50% gelation is about 3 to about 30 minutes at a temperature of about 37 °C. In additional embodiments, the time to 50% gelation is about 4 to about 10 minutes at a temperature of about 37 °C. In yet another embodiment, the time to 50% gelation is about 5 to about 10 minutes or about 10 to about 20 minutes at a temperature of about 37 °C.
[0075] The disclosed ECM hydrogel may have a flow viscosity suitable for injection into the esophagus. In some embodiments, the ECM hydrogel has a flow viscosity of about 10 to about 100 Pa*s at a shear rate of 0.2 / s, e.g., about 10, 20, 30, 40, 50, 60, 70, 80, or 90 Pa*s. In additional embodiments, the flow viscosity is about 0.1 to about 100 Pa*s at a shear rate of about 0.1 / s and about 0.01 to about 0.2 Pa*s at a shear rate of 1000 / s. In more embodiments, the flow viscosity is about 0.1 to about 30 Pa*s at a shear rate of 1 / s and about 0.02 to about 0.8 Pa*s at a shear rate of about 100 / s.
[0076] In some embodiments, the ECM hydrogel has a flow viscosity of about 0.1 to about 30 Pa*s at a shear rate of 1 / s. In additional embodiments, the ECM hydrogel has a flow viscosity of about 0.1 to about 100 Pa*s at a shear rate of about 0.1 / s. In certain non-limiting examples, the ECM hydrogel has a flow viscosity of 0.5 to about 50 Pa*s, or the ECM hydrogel has a flow viscosity of about 1 to about 40 Pa*s at a shear rate of 0.1 / s. Exemplary flow viscosities are approximately 0.1, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, or 100 Pa*s at a shear rate of 0.1 / s.
[0077] In another embodiment, the ECM hydrogel has a flow viscosity of about 0.01 to about 0.20 Pa*s at a shear rate of 1000 / s, or about 0.01 to about 0.10 Pa*s at a shear rate of 1000 / s, for example 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.10, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.19, or 0.2 Pa*s.
[0078] In more embodiments, the ECM hydrogel has about 0.02 to about 0.8 Pa*s at a shear rate of 100 / s, or about 0.1 to about 0.8 Pa*s at a shear rate of 100 / s, for example about 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, or 0.08 Pa*s.
[0079] In another embodiment, the ECM hydrogel has a flow viscosity of about 0.1 to about 30 Pa*s, e.g., about 1 to about 20 Pa*s, or 1 to about 10 Pa*s, or 0.5 to 25 Pa*s, e.g., about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, or 30 Pa*s at a shear rate of 1 / s. The flow viscosity may be, for example, 5, 10, 20, or 30 Pa*s at a shear rate of 1 / s. In another embodiment, the ECM hydrogel has a flow viscosity of about 0.02 to about 0.8, such as about 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, or 0.8 at a shear rate of 100 / s. The flow viscosity may be about 0.1 to about 30 Pa*s at a shear rate of 1 / s and about 0.02 to about 0.8 Pa*s at a shear rate of 100 / s. In a further embodiment, the flow viscosity is about 1 to about 10 Pa*s at a shear rate of 1 / s and about 0.02 to about 0.5 at a shear rate of 100 / s.
[0080] In additional examples, the ECM hydrogel has a flow viscosity of about 10 to about 100 Pa*s at a shear rate of 0.1 / s. In other examples, the ECM hydrogel has a flow viscosity of about 0.01 to about 0.2 Pa*s at a shear rate of 1000 / s. In other examples, the ECM hydrogel has a flow viscosity of about 1 to about 40 Pa*s at a shear rate of 0.1 / s and a flow viscosity of 0.01 to 0.2 Pa*s at a shear rate of 1000 / s.
[0081] The disclosed ECM hydrogel has a hardness of i) about 10 to about 400 Pascal (Pa), ii) about 10 to about 600 Pa, iii) about 5 to about 1,000 Pa, iv) about 10 to 1,000 Pa, or v) about 10 to 70 Pa. The ECM hydrogel may have a hardness of about 10 to about 300 Pascal (Pa), for example, about 10 to about 70 Pa, about 10 to about 100 Pascal (Pa), or about 10 to about 150 Pa, about 10 to about 200 Pa, or about 10 to about 300 Pa. In some embodiments, the disclosed ECM hydrogel has a hardness of about 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, or 70 Pa. In another embodiment, the disclosed ECM hydrogel has a hardness of about 10 to about 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, or 400 Pa. In additional examples, the disclosed ECM hydrogel has a hardness of about 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, or 300 Pa.
[0082] In some embodiments, the ECM concentration in the hydrogel is about 2 mg / ml to about 20 mg / ml, e.g., about 8 mg / ml to about 12 mg / ml or about 2 mg / ml to about 16 mg / ml. In other embodiments, the ECM concentration in the hydrogel is about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 mg / ml. Exemplary concentrations in use include, but are not limited to, about 9 mg / ml to about 11 mg / ml, and about 10 mg / ml to about 12 mg / ml. Concentrations of additional examples include about 8 mg / ml to about 10 mg / ml, about 8 mg / ml to about 11 mg / ml, about 8 mg / ml to about 13 mg / ml, about 8 mg / ml to about 14 mg / ml, about 8 mg / ml to about 15 mg / ml, and about 8 mg / ml to about 16 mg / ml. Concentrations of additional examples also include about 6 mg / ml to about 12 mg / ml, about 13 mg / ml, about 14 mg / ml, about 15 mg / ml, or about 16 mg / ml.
[0084] The disclosed ECM hydrogel may be provided as a component of a kit. The ECM hydrogel may be provided in a frozen or freeze-dried form. In some embodiments, the kit may comprise one container containing the hydrogel, such as in a freeze-dried form, which is a component necessary to form the hydrogel; one container containing a solution for dissolving the freeze-dried hydrogel; and optionally, a container containing a neutralizing solution for neutralizing the dissolved form. In other embodiments, the kit may comprise a container containing the dissolved hydrogel and a second container containing a neutralizing agent.
[0085] Optionally, these kits include additional components, such as packaging, instructions, and various other reagents, such as buffers, substrates, or other therapeutic ingredients. The kit may include a container and a label or package insert on or associated with the container. Suitable containers include, for example, bottles, vials, syringes, etc. Containers may be formed from various materials, such as glass or plastic. The container typically holds a composition containing an ECM hydrogel, which, for example, in a frozen or lyophilized form, is effective in suppressing esophageal inflammation in the subject and / or alleviating the effects of esophageal inflammation. In several embodiments, the container may have a sterile access port (for example, the container may be a solution bag or a vial with a stopper that can be punctured into a vein with a subcutaneous injection needle). A label or package insert indicates that this composition is used in endoscopic procedures for specific conditions, such as colorectal cancer.
[0086] Generally, additional instructions for use are included on the label or in the package insert. The package insert typically contains instructions customarily included in the commercial packaging of the therapeutic product, which include information regarding indications, usage, dosage, administration, contraindications, and / or warnings concerning the use of the therapeutic product. Educational materials may be prepared in electronic format (e.g., computer diskette or compact disk) or as visual materials (e.g., video files). The kit may also include additional components, such as needles or catheters, that facilitate the specific application for which the kit is designed. The kit may additionally include buffers and other reagents routinely used in the execution of specific methods. The kit and its appropriate contents are well known to those skilled in the art.
[0087] Methods of Treatment
[0088] A method for separating the mucosa and submucosa from the inferior muscle in the esophagus of a subject is disclosed in the present application, wherein the method comprises submucosally injecting a pharmaceutical composition comprising an extracellular matrix (ECM) hydrogel into the esophagus to form a cushion between the submucosa and the inferior inferior muscle in the esophageal region, wherein the ECM hydrogel is not a bladder ECM hydrogel (e.g., UBS or UBM). The method may be an EMR or an EMD.
[0089] EMR is an endoscopic technique developed to remove adherent or flat neoplasms confined to the superficial layers (mucosa and submucosa) of the gastrointestinal tract. EMR is generally used to remove lesions smaller than 2 cm or to remove larger lesions in fragments. EMR also plays an important role in evaluating resected specimens for accurate pathological staging. In contrast to polypectomy, EMR involves elevating the lesion from the muscle layer by injecting a normal saline (NS) solution into the submucosa. EMR is also useful for obtaining specimens for accurate histopathological staging to determine the risk of lymph node metastasis. EMR facilitates the complete removal of the infected mucosa by resecting the middle or deeper portions of the intestinal wall submucosa. Various EMR techniques have been described, and four methods, including snare resection, are commonly used. (1) the inject and cut method; (2) the inject, lift, and cut method; (3) cap-assisted endoscopic mucosal resection (EMRC); and (4) ligation-assisted EMR (EMRL). In the injection and cut technique, the diseased mucosa generates a submucosal fluid cushion, which lifts and grasps the muscle layer, tightens it using an electrosurgical snare, and then resects it. However, injecting into the thin submucosal layer is a delicate process, the injected solution tends to dissipate rapidly, and it is difficult to capture flat and compressed lesions with a snare compared to protruding lesions; furthermore, lesions that are large or located in hard-to-reach areas may be difficult to remove (Uraoka et al., Drug Design, Development and Therapy 2008 : 2 131-138).Injection-assisted endoscopic mucosal resection (Injection-assisted EMR) is frequently used for large, flat colon polyps.
[0090] ESD was specifically developed to remove larger lesions. Lesions are resected en-bloc even by using an electric surgical knife to separate them directly along the submucosal layer. Although ESD is predicted to replace conventional surgery in the treatment of certain cancer stages, it requires more endoscopic skills and experience than EMR due to higher rates of perforation and bleeding complications. ESD can utilize numerous electric surgical knives, such as insulation-tipped diathermic knives, needle knives, hook knives, flex knives, triangle-tip knives, flush knives, splash needles, and small-caliber-tip transparent hoods. These knives can be used in conjunction with high-frequency electrosurgical current (HFEC) generators. The characteristics of ESD are the following three steps: (1) elevating the lesion from the muscle layer by injecting fluid to form a submucosal cushion; (2) circumferential cutting of the mucosa surrounding the lesion; and (3) separation of the submucosal connective tissue beneath the lesion (see Kakushima et al., Wold J. Gstroenterol. 14 (9): 2962-2967, 2008, incorporated by reference in this application). While various submucosal injection solutions have been previously developed and found satisfactory for use during EMR, introducing longer ESD surgeries required longer-lasting solutions that aid in identifying the cutting line during the separation of the submucosal layer (Uraoka et al., Drug Design, Development and Therapy 2008 : 2 131-138). The currently disclosed method meets these requirements.
[0091] Submucosal injections used in EMR involve injecting fluid into the submucosal cushion to facilitate the separation of tissue to be removed immediately before the target lesion is grasped with a snare, thereby reducing the risk of thermal injury, perforation, and hemorrhage, and also facilitating resection. Submucosal injections play a crucial role in EMR surgery because the solution must remain in place for a sufficient period and form a hemispherical shape to facilitate grasping with a snare. Additionally, providing a sufficiently high submucosal elevation enables safe submucosal transection during ESD (Uraoka et al., Drug Design, Development and Therapy 2008: 2 131-138). Furthermore, since surgery causes inflammation, the cushion remaining at the surgical site must provide anti-inflammatory action. ECM hydrogels relieve strictures and promote re-epithelialization. The currently disclosed method also meets these requirements.
[0092] In some embodiments, the disclosed method uses an ECM hydrogel that has anti-inflammatory properties, is inexpensive, non-toxic, easy to inject, and provides a high and long-lasting submucosal cushion. The ECM hydrogel is administered in a pre-gel form and then gels at the injection site to form a cushion. The cushion is separated during surgery, leaving some of the hydrogel in the underlying propria to aid in healing. The disclosed ECM hydrogel facilitates the closure of a wound created by the removal of the resected mucosa / submucosal tissue. In some embodiments, this surgery is an ESD. In other embodiments, this surgery is an EMR.
[0093] Normal saline (NS) and thinner solution (e.g., ELEVIEW TM (See U.S. Patent No. 9,226,996) Although these have been used as submucosal cushions for endoscopic resection, it has been difficult to create an adequate submucosal fluid cushion, maintain it at the desired height, and keep the cushion in the desired position due to the rapid dispersion of the solution, which is an inherent characteristic of these solutions. Furthermore, once the mucosa / submucosal membrane is removed in ESD, these agents do not remain in the underlying propria. Additionally, these agents do not aid in healing processes such as reducing inflammation. The use of ECM hydrogels meets these requirements.
[0094] The ECM hydrogel disclosed in this application may be used in any ESD or EMR. As disclosed in U.S. Patent No. 9,364,580 incorporated by reference in this application, the endoscopic injection needle is a device comprising a relatively long catheter with a length (up to approx. 230 cm) and an internal injection tube slidably positioned with a distal injection needle. A proximal operating handle is coupled to the catheter and injection tube to move one relative to the other when necessary. Fluid access to the injection tube is typically provided through the rear connector of the handle. The endoscopic injection needle device is typically delivered to the injection site through the working channel of the endoscope. To protect the lumen of the endoscopic working channel from damage, the distal injection needle is withdrawn into the lumen of the catheter by manipulating the handle of the injection needle device before inserting the device into the endoscope. This prevents the sharp end of the injection needle from being exposed as the device moves through the lumen of the endoscope. When the distal end of the endoscopic injection needle device is positioned at the injection site, the handle is manipulated again to move the injection needle from the lumen of the catheter to the distal end. When advanced to the furthest position, the length of the exposed part of the injection needle is approximately 4-6 mm.
[0095] After puncturing the injection site, the pregel-type ECM contained in a 5ml to 10ml syringe, provided with a luer-lock fitting connected to the needle handle, can be delivered through the injection tube and needle to an injection site such as between the submucosal area and the inferior propria.
[0096] Injection needles and other accessories commonly used during endoscopy, such as polypectomy snares, clipping devices, and biopsy forceps, pass through one or more specific channels of the endoscope, generally referred to as working channels or surgical channels. The inner diameter of the working channel may vary depending on the type of endoscope used. However, the most common endoscopes used for GI endoscopy have working channels with inner diameters ranging from approximately 2 mm to approximately 5 mm. Generally, manufacturers of endoscope accessories produce accessories with outer diameters that fit all working channels. In some embodiments, the outer diameter of the endoscope injection needle or catheter is in the range of 1.9 mm to 2.3 mm, such as approximately 1.9, 2.0, 2.1, 2.2, or 2.3 cm. Therefore, considering that the internal injection tube is contained within the external catheter, the inner diameter is generally 1 mm or less. The disclosed ECM hydrogel in the form of a pregel can easily pass through these catheters.
[0097] ECM hydrogel in the form of a pregel can be used for endoscopic resection to place a liquid volume in the submucosal layer that acts as a cushion when in place by using a syringe to draw an emulsion volume from a primary container and injecting an appropriate volume of the emulsion using an endoscopic injection needle inserted into the working channel of the endoscope just below the superficial mucosal layer: even if the lesion is flat and does not protrude into a lumen such as the esophageal lumen, the endoscopic operator can easily resect the discovered mucosal lesion due to the elevation of the mucosal surface during the endoscopic procedure.
[0098] If the cushion contains at least one dye, it can assist the endoscopic operator in visualizing structures beneath the mucosa (e.g., the submucosal layer and the external muscle wall), thereby reducing the risk of damage to said structures for the operator performing the resection. The use of dye allows for the visualization of the cushion cavity and the mucosal base. Removing a lesion from the mucosal surface creates a wound on the mucosa. The persistence of the cushion created by the injected volume of the pharmaceutical composition enables endoscopic resection to be performed without the need for re-injection. An ECM hydrogel in the form of a pregel is injected submucosally into a site of interest in the target esophagus, such as the site of a lesion or tumor, to form a cushion between the submucosal layer and the inferior propriomus in that area of the esophagus. As the cushion detaches, a portion of the ECM hydrogel remains within the inferior propriomus, aiding the healing process.
[0099] The disclosed method is used in the esophagus. In a non-limiting example, the method includes a method for isolating an esophageal carcinoma or adenocarcinoma from the esophagus. In another non-limiting example, the method includes incising the mucosa and submucosa from the esophagus of a subject with Barrett's esophagus.
[0100] As disclosed in this application, the ECM hydrogel is at a temperature below the gelation temperature, for example, below room temperature (e.g., about 25°C). It is maintained at. The ECM hydrogel may be maintained at 25ºC or 4ºC, for example, before administration. Then, an effective amount of the ECM hydrogel in pregel form is administered into the subject's esophagus. The ECM hydrogel may be provided in a freeze-dried or frozen form and may be reconstituted immediately before administration to the subject's tracheal site.
[0101] The disclosed method is used on any subject, including humans and veterinary subjects. Subjects may be of any age. In one embodiment, a composition in the form of a pregel containing an ECM hydrogel is injected into a human target tissue to form a cushion, and then optionally undergoes an endoscopic procedure such as resection. The ECM may be derived from the same species as the subject being treated or from a different species. In some embodiments, the subject is human and the ECM hydrogel is derived from human and / or porcine tissue. In other embodiments, the ECM hydrogel is derived from non-human primates, dogs, cats, horses, or cattle. The ECM may also be available from commercial sources. The ECM hydrogel is not a bladder ECM hydrogel such as UBM or UBS.
[0102] The disclosed method is invasive because it requires an injection to separate the mucosa and submucosa from the underlying muscle in the esophageal region. Any method disclosed in this application may involve submucosally injecting a pharmaceutical composition comprising an ECM hydrogel into the subject's esophagus to form a cushion between the submucosa and the underlying muscle in the esophageal region. The ECM hydrogel has the following characteristics: a) a 50% gelation time of less than 20 minutes at a temperature of about 37°C; b) a flow viscosity suitable for injection into the esophagus; and c) a hardness of about 10 to about 400 Pascal (Pa). The ECM hydrogel gels to separate the mucosa and submucosa from the underlying muscle and inhibits inflammation in the subject's esophageal region. The ECM hydrogel may be administered in a pre-gel form via an endoscope or catheter.
[0103] In some embodiments, the resection is endoscopic mucosal resection or esophageal endoscopic submucosal dissection, and the method includes a method of incising an esophageal carcinoma or adenocarcinoma from the esophagus. In more embodiments, the method includes separating the mucosa and submucosal from the esophagus of a patient with dysplasia. In more embodiments, the method includes separating the mucosa and submucosal from the esophagus of a subject having Barrett's esophagus.
[0104] The method may also include performing endoscopic resection on the cushion. In some embodiments, the method includes dividing the cushion so that the hydrogel is retained in the lower proprioceptive muscle of the esophagus and the mucosa and submucosa are removed from the esophageal region. In some non-limiting examples, the portion of the hydrogel cushion retained in the lower proprioceptive muscle downregulates pro-inflammatory macrophage activation in the esophagus.
[0105] ECM can be derived from any tissue other than the bladder. Therefore, the hydrogel is not UBM or UBS. In some embodiments, the time to 50% gelation of the hydrogel is less than 30 minutes at a temperature of about 37 °C. In some specific non-limiting examples, the time to 50% gelation is about 2 to about 30 minutes at about 37 °C. In other specific non-limiting examples, the time to 50% gelation is about 2 to about 10 minutes at about 37 °C. In additional non-limiting examples, the time to 50% gelation is about 3 to about 10 minutes.
[0106] In additional examples, the flow viscosity of the pregel form is sufficient for injection into the esophagus. In some examples, the flow viscosity of the ECM hydrogel is about 0.1 to about 100 Pa*s at a shear rate of about 0.1 / s and about 0.01 to about 0.2 Pa*s at a shear rate of 1000 / s. In some non-limiting examples, the flow viscosity is about 30 Pa*s at a shear rate of 1 / s and about 0.02 to about 0.8 Pa*s at a shear rate of about 100 / s.
[0107] In additional examples, the ECM hydrogel has a hardness of about 10 to about 300 Pascal (Pa) when introduced into tissue; wherein the ECM hydrogel has a hardness of 10 to 70 Pa. In additional examples, the ECM concentration of the hydrogel is 2 mg / ml to about 16 mg / ml.
[0108] The ECM hydrogel may be produced by any method disclosed in this application. In some embodiments, the ECM hydrogel is produced by the step of (a) dissolving the decellularized extracellular matrix (ECM) by digesting the tissue with an acidic protease in an acidic solution to produce digested ECM; and (b) raising the pH of the digested ECM to a pH of 7.2 to 7.8 to produce a neutralized digested solution. In additional embodiments, raising the pH of the digested ECM in step (b) comprises raising the pH of the digested ECM by adding a base or an isotonic buffer. In additional embodiments, an acidic protease such as pepsin, trypsin, or a combination thereof is used. The ECM hydrogel may be an esophageal ECM hydrogel.
[0109] In some embodiments, the ECM hydrogel is maintained at 25 °C or lower before administration to the subject. In some embodiments, the ECM hydrogel is maintained at approximately 4 °C to approximately 28 °C, such as approximately 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, or 28 °C. The ECM hydrogel may be maintained at approximately 4 °C immediately before use, used at approximately 4 °C to approximately 25 °C, or warmed to approximately 25 °C. In some embodiments, temperature control ensures that the ECM hydrogel remains in a pre-gel form, and is therefore suitable for injection between the submucosal and inferior propria. In additional examples, the hydrogel gels when administered to a subject, such as when reaching a temperature of 37 °C.
[0110] Example
[0111] ELEVIEW TM and ECM hydrogels are different biomaterials. ELEVIEW TM Aries Pharmaceuticals, Inc. (Dublin, Ireland) is a commercially available low-viscosity emulsion of Poloxamer 188, which is clinically used to provide submucosal elevation for EMR and ESD surgeries. ELEVIEW TM It is disclosed herein that it does not form a stably formed hydrogel at 37 °C and remains in a liquid state over one hour at 37 °C. In contrast, 12 mg / mL esophageal ECM hydrogel (eECM) (prepared according to the method disclosed in this application, i.e., by protease digestion of ECM) forms a hydrogel that is stably formed at 37 °C (body temperature). ELEVIEW TM and eECM can be injected submucosally. Ideal biomaterials adhere to both layers. ELEVIEW for muscle TMThere was no difference in mucoadhesive strength between and eECM 12 mg / mL. Surprisingly, eECM ELEVIEW TM The mucoadhesion to the mucosa was stronger. Furthermore, eECM demonstrated biological activity through macrophage polarization with a remodeling phenotype. This demonstrates that extracellular matrix hydrogels can be effectively used as submucosal cushions and thus can be used to separate the submucosa from the underlying proprioceptive muscle.
[0112] Example (Example 1)
[0113] Materials and Methods
[0114] Rheology
[0115] ELEVIEW TM The viscoelastic properties of eECM 12 mg / mL were measured using a temperature-controlled 40 mm parallel plate rheometer (AR2000). Samples were maintained at 4 °C and loaded into the rheometer using a parallel plate structure pre-cooled to 10 °C. Mineral oil was used to seal the sample plate interface and minimize evaporation during testing. A series of rheological tests were performed sequentially on each sample. Shear rate range (0.1–1000 s⁻¹) -1A steady-state flow curve was performed at 10 °C to determine the viscosity profile of the sample. The plate temperature was rapidly increased from 10 °C to 37 °C, and an oscillatory time sweep was performed at 37 °C with a small oscillatory strain of 0.5% at a frequency of 1 rad / s to measure the maximum storage modulus (G'), maximum loss modulus (G''), and gelation kinetics. Data were extracted and analyzed in Prism (version 6, GraphPad) for statistical analysis (n = 3).
[0116] Muco-adhesion to muscularis
[0117] The porcine mucosa and muscularis were mechanically separated by peeling off the mucosa and submucosa from the underlying muscular layer. ELEVIEW TM and eECM (12 mg / mL) were pipetted into a 6-well plate. ELEVIEW TM Alternatively, by adhering mucosa or muscle to the bottom surface of a hemisphere (40 mm diameter) placed on the eECM, ELEVIEW TMAlternatively, the surface area of the mucosa or muscle in contact with the eECM was kept constant throughout all tests. To attach the structure to the mucosa or muscle, it was incubated at 37 °C for 1 hour. After 1 hour, the structure was placed on an MTS Insight tensile machine equipped with a 10 N load cell and a ball burst attachment, and the measurement frequency was set to 10 Hz. The ball burst attachment was firmly attached to the hemisphere, and the hemisphere was raised at 5 mm / min. The maximum force value was considered as the adhesion force subtracted by the force applied to the freely suspended structure. Measurements were permitted only when delamination occurred between the mucosa or muscle and the hydrogel (n = 3).
[0118] Extracorporeal submucosal fluid cushioning performance
[0119] (Ex-vivo submucosal fluid cushion performance)
[0120] The pig's esophagus was placed in a 37°C incubator, and the temperature was monitored with a thermometer until the tissue reached 37°C. After reaching the target temperature, 2 mL of ELEVIEW was administered using a 23G needle. TM Alternatively, neutralized eECM was injected submucosally at a dose of 12 mg / mL. The eECM was kept on ice during surgery. Tissues were evaluated and photographed with metric witness at 15-minute intervals for up to 75 minutes. Tissues were incubated at 37 °C throughout the surgery. After 75 minutes, the site where the test agent was injected was isolated and evaluated. ImageJ was used to quantify mucosal elevation following agent injection throughout the experiment.
[0121] Macrophage isolation and activation
[0122] Mouse bone marrow was harvested using the previously described method [1, 2]. Briefly, female 6-8 week old C57bl / 6 mice (Jackson Laboratories, Bar Harbor, ME) were euthanized by CO2 inhalation and cervical dislocation. Under sterile conditions, the skin from the proximal hind limb to the foot was removed, the tarsus and stifle were dislocated, and the tibia was separated. The coxafemoral joint was dislocated to separate the femur. After removing excess tissue, the bone was stored on ice and rinsed in a sterile dish containing a macrophage complete medium composed of DMEM (Gibco, Grand Island, NY), 10% fetal bovine serum (FBS) (Invitrogen, Carlsbad, CA), 10% L929 supernatant [2], 50 µM beta-mercaptoethanol (Gibco), 100 µg / ml penicillin, 100 µg / ml streptomycin, 10 mM non-essential amino acid (Gibco), and 10 mM herpes buffer. The end of the bone was incised and the marrow cavity was drained into the complete medium to collect the bone marrow. Cells were washed and plated at 2 x 10⁶ cells / ml and allowed to differentiate into macrophages for 7 days at 37 °C, 5% CO₂, and the medium was completely replaced every 48 hours as previously described [3].After 7 days, the generated naive macrophages were treated with a basic medium consisting of 10% FBS, 100 µg / ml streptomycin, 100 µg / ml penicillin in DMEM, and one of the following conditions as previously described: (1) 20 ng / ml IFNγ and 100 ng / ml LPS to promote an M1-like phenotype, (2) 20 ng / ml IL-4 to promote an M2-like phenotype, (3) 250 µg / ml pepsin control buffer, (4) 250 µg / ml esophageal ECM, or (5) an equal amount of ELEVIEW for 24 hours at 37°C, 5% CO2. TM [4].
[0123] Immuno-labeling of Macrophages
[0124] After 24 hours, the macrophages were washed and fixed with 2% paraformaldehyde. After PBS washing, the cells were incubated at room temperature for 1 hour in a blocking solution consisting of 0.1% Triton-X 100, 0.1% Tween 20, 4% normal goat serum, and 2% bovine serum albumin (BSA) to prevent non-specific antibody binding. The following primary antibodies were diluted in blocking solution: (1) monoclonal anti-F4 / 80 (Abcam, Cambridge, MA), a pan-macrophage marker, diluted 1:100; (2) polyclonal anti-iNOS (Abcam, Cambridge, MA), an M1 marker, diluted 1:100; (3) polyclonal anti-Fizz1 (Peprotech, Rocky Hill, NJ), an M2 marker, diluted 1:100; and (4) polyclonal anti-Fizz1 (Abcam, Cambridge, MA), an M2-like marker for liver arginase, diluted 1:100 [5-7]. Cells were cultured in the primary antibodies at 4 °C for 16 hours. After washing with PBS, cells were incubated at room temperature for 1 hour in a secondary antibody conjugated with a fluorophore (Alexa Fluor goat anti-rat 488 or goat anti-rabbit 488, Invitrogen). After washing with PBS, nuclei were counterstained with 4'6'-diamidino-2-phenylindole (DAPI) before imaging three 200X fields using a live-cell microscope.Light exposure time was standardized to a negative isotype control and maintained constant throughout the image. The images were quantified using CellProfiler Image Analysis software to obtain positive F4 / 80, iNOS, Fizz1, and Arginase1 percentages.
[0125] Use of ECM as a submucosal fluid cushion for EMR in vivo
[0126] (In-vivo use of ECM as submucosal fluid cushion for EMR)
[0127] Anesthesia is induced with acepromazine (0.01 mg / kg, SC) and ketamine (5-11 mg / kg), and surgical plane anesthesia is maintained with 1-5% isoflurane via an endotracheal tube. During surgery and the immediate postoperative period, 2 ml / kg / h of lactated Ringer's solution is administered intravenously to the animal. Temperature is controlled via a hot water circulating heating pad placed beneath the animal. Physiological parameters such as heart rate, respiratory rate, body temperature, and responsiveness are monitored during surgery. Antibiotic prophylaxis with 25 mg / kg of cefazolin is administered prior to the start of surgery.
[0128] The animal is placed in a supine position, and the trachea is evaluated using a Pentax EG3430K endoscope. After confirming the tracheal reference point, the mucosa and submucosa of the resection site are separated using an 8 mg / ml blue-stained hydrogel injection with an Olympus Injectorforce 4 mm 23G needle at 4°C. This temperature is maintained at all times to prevent needle gelation and potential blockage. Approximately 2–5 ml of blue gel is injected per site. The entire 5 cm length of the mucosal perimeter (100%) is removed using band-ligation EMR technology. For EMR, a Cook Duette Kit with a ligation band is used. The mucosa is then resected using a snare.
[0129] Statistics
[0130] 2-way ANOVA was used to compare the effects of the independent variable shear rate and sample on the dependent variable viscosity, and also to compare the effects of the independent variable sample and coefficient type on the dependent variable modulus. The Sidak post-hoc multiple comparisons test was used; significance was determined using 95% confidence intervals, and p-values were adjusted for multiple comparisons. ELEVIEW TM A t-test was performed on mucoadhesive strength by comparing with esophageal extracellular matrix (eECM) 12 mg / mL.
[0131] Example 2
[0132] Viscoelastic properties
[0133] ELEVIEW TM It was significantly less viscous than eECM 12 mg / mL at a shear rate of 0.1 1 / s (p < 0.0001), and the difference tended to be less pronounced at 1 1 / s (p = 0.054). Fig. 1A ). ELEVIEW TM It fails to form a stable hydrogel form because the average loss factor (G'') (0.09±0.04 Pa) is greater than the average storage factor (G') (0.05±0.01 Pa), whereas eECM 12 mg / mL does not meet the definition of a stably formed ECM hydrogel (Freytes et al., Biomaterials, 2008. 29 (11): p. 1630-7) has a storage factor (G') (56.95±66.72 Pa) that is larger than the loss factor (G'') (7.62±6.30 Pa) ( Fig. 1B ). ELEVIEW TM A representative graph for the time sweep of is ELEVIEW TM ga does not form a hydrogel ( Fig. 1C ), on the other hand, the storage factor of eECM 12 mg / mL increases in an S-shape and remains steady over time ( Fig. 1D ). Therefore, the gelation time to 50% gelation can be calculated for eECM 12 mg / mL (4.5±3.5 min), but ELEVIEW TM It cannot be calculated for ( Fig. 1E ).
[0134] Example 3
[0135] Mucoadhesive force to the muscularis
[0136] ELEVIEW TM (0.16±0.05 N) and eECM (0.21±0.08 N) did not show significantly different mucosal adhesion to muscle (Fig. 2A ). eECM is ELEVIEW TM The mucosal adhesion strength (0.37±0.02N) was higher than that of (0.15±0.06N) (p = 0.0053) ( Fig. 2B ).
[0137] Example 4
[0138] Macrophage activation
[0139] Macrophages exposed to eECM exhibited activation of FIZZ1, an anti-inflammatory marker, with minimal iNOS expression (anti-inflammatory marker). iNOS expression is ELEVIEW TM , eECM and the carrier (pepsin) control were similar ( Fig. 3 ). ELEVIEW TM It did not show any biological activity.
[0140] Example 5
[0141] In vitro submucosal fluid cushioning performance
[0142] (Ex-vivo submucosal fluid cushion performance)
[0143] ELEVIEW™ and eECM successfully created a fluid cushion by injecting 2 mL of the test agent into the esophagus. Both test agents could be easily injected with a 23G needle. ELEVIEW™ appeared to diffuse from the moment of injection. Height measurements and visible appearance confirmed these observations. Fig. 4 The esophagus experienced a loss of elevation between 0 and 15 minutes ( Fig. 4 The loss of elevation was greater in ELEVIEW™ than in eECM. Although the decrease in elevation continued in both test agents in the esophagus, it was clear that the loss was greater in ELEVIEW™.
[0144] The results of separation after 75 minutes showed a difference between ELEVIEW™ and eECM in the esophagus. The site injected with ELEVIEW™ exhibited a viscous fluid with no distinct adhesion to the mucosa or underlying muscle layer. The site previously injected with eECM showed clear and defined gel clumps attached to the mucosa and underlying muscle ( Fig. 4 This is consistent with the above result (see Example 2) demonstrating that ELEVIEW™ cannot form a gel ( Fig. 1D ).
[0145] Example 6
[0146] Use of ECM as a submucosal fluid cushion for in vivo EMR
[0147] (In-vivo use of ECM as submucosal fluid cushion for EMR)
[0148] The ECM hydrogel is delivered through a long endoscopic needle without resistance. Mucosal elevation was successfully achieved and maintained to facilitate EMR surgery, and blue dye indicated the site where an incision was made for removal. The tissue was removed using a snare. Upon visual inspection, the removed mucosal tissue contains a portion of the gel. The blue dye of the hydrogel appears to diffuse across the circumference of the trachea after mucosal removal, and the entire circumference is achieved using the hydrogel.
[0150] It should be recognized that, in light of the many possible embodiments to which the principles of the disclosed invention may be applied, the exemplified embodiments are merely preferred examples of the invention and should not be construed as limiting the scope of the invention. Rather, the scope of the invention is defined by the following claims. Accordingly, we assert that everything contained within these claims and in the spirit thereof is the invention.
Claims
Claim 1 A pharmaceutical composition comprising an extracellular matrix (ECM) hydrogel, wherein the extracellular matrix (ECM) hydrogel comprises: a) a 50% gelation time of less than 30 minutes at a temperature of about 37 °C; b) a flow viscosity for esophageal injection of about 0.1 to about 100 Pa*s at a shear rate of about 0.1 / s and about 0.01 to about 0.2 Pa*s at a shear rate of 1000 / s; and c) a stiffness of about 10 to about 400 Pascal (Pa). and d) the concentration of the extracellular matrix in the hydrogel is characterized to be 10 mg / ml to about 20 mg / ml, and is intended to be used to separate the mucosa and submucosa from the muscularis propria of the subject's esophageal region and to suppress inflammation caused by the separation of the mucosa and submucosa from the muscularis propria in the esophageal region, wherein the extracellular matrix (ECM) hydrogel is an esophageal ECM hydrogel, and wherein the pharmaceutical composition is formulated for submucosal injection into the subject's esophagus and is characterized by forming a cushion between the submucosa of the esophageal region and the underlying muscularis propria. Claim 2 A pharmaceutical composition according to claim 1, characterized in that the 50% gelation time is about 2 to about 30 minutes at about 37 °C. Claim 3 A pharmaceutical composition according to claim 1, characterized in that the 50% gelation time is about 2 to about 10 minutes at about 37 °C. Claim 4 A pharmaceutical composition according to claim 2, characterized in that the 50% gelation time is about 3 to about 10 minutes. Claim 5 delete Claim 6 A pharmaceutical composition according to claim 1, characterized in that the flow viscosity is about 0.1 to about 30 Pa*s at a shear rate of 1 / s and about 0.02 to about 0.8 Pa*s at a shear rate of about 100 / s. Claim 7 A pharmaceutical composition according to claim 1, characterized in that the extracellular matrix (ECM) hydrogel has a hardness of 10 to 300 Pa. Claim 8 delete Claim 9 delete Claim 10 A pharmaceutical composition according to claim 1, characterized in that the extracellular matrix (ECM) hydrogel is administered through an endoscope or catheter. Claim 11 A pharmaceutical composition according to claim 1, wherein the extracellular matrix (ECM) hydrogel is prepared by the following steps: (a) preparing a decellularized ECM by dissolving the decellularized ECM by digesting the tissue with an acid protease in an acidic solution; and (b) producing a neutralized decomposition solution by raising the pH of the decomposed ECM to a pH between 7.2 and 7.
8. Claim 12 A pharmaceutical composition according to claim 11, characterized in that raising the pH of the decomposed ECM in (b) includes raising the pH of the decomposed ECM by adding a base or an isotonic buffer. Claim 13 A pharmaceutical composition according to claim 11, characterized in that the acidic protease is pepsin, trypsin, or a combination thereof. Claim 14 A pharmaceutical composition according to claim 1, characterized in that the extracellular matrix (ECM) hydrogel is maintained at 25 °C or lower before administration to a subject. Claim 15 A pharmaceutical composition according to claim 1, characterized in that the extracellular matrix (ECM) hydrogel is injected via an endoscope or a catheter. Claim 16 A pharmaceutical composition according to claim 15, characterized in that the extracellular matrix (ECM) hydrogel is maintained at 25 °C or lower before being injected into a subject. Claim 17 A pharmaceutical composition according to claim 1, characterized in that the inflammation occurs by isolating esophageal dysplasia, adenocarcinoma, or carcinoma from the esophagus. Claim 18 A pharmaceutical composition according to claim 17, characterized in that the inflammation occurs by separating the mucosa and submucosa from the esophagus of a subject having Barrett's esophagus. Claim 19 A pharmaceutical composition according to claim 1, further comprising performing an endoscopic resection procedure in a cushion to remove the separated mucosa and submucosa. Claim 20 A pharmaceutical composition according to claim 19, characterized in that the resection is endoscopic mucosal resection or endoscopic submucosal dissection. Claim 21 A pharmaceutical composition according to claim 20, wherein the above-mentioned resection is characterized by dividing the cushion so that the hydrogel is retained in the lower muscularis propria of the esophagus and the mucosa and submucosa are removed from the esophageal region. Claim 22 A pharmaceutical composition according to claim 1, characterized in that the subject is a human. Claim 23 A pharmaceutical composition according to claim 1, characterized in that the extracellular matrix (ECM) hydrogel has a 50% gelation time of less than 20 minutes at about 37 °C. Claim 24 A pharmaceutical composition according to claim 1, characterized in that the separation comprises endoscopic mucosal resection or endoscopic submucosal dissection. Claim 25 delete
Citation Information
Patent Citations
Method and composition for treating inflammatory bowel disease without colectomy
KR1020160016778A
ECM hydrogels for the treatment of esophageal inflammation
KR1020190120258A
Devices and methods for agent-assisted medical procedures
US20060070631A1
Apparatus and Method for Endoscopic Submucosal Dissection
US20110208158A1
Collagen sol for submucosal local injection
JP2018080136A
